Taysha Gene Therapies (TSHA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 2, 2025, with virtual attendance available for shareholders as of April 3, 2025.

• Shareholders are encouraged to review proxy materials online and vote in advance by June 1, 2025.

Voting matters and shareholder proposals

• Election of two Class II Director nominees, Phillip B. Donenberg, CPA, and Sukumar Nagendran, MD, to serve until the 2028 Annual Meeting.

• Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2025.

• Approval of an amendment to increase authorized common stock from 400,000,000 to 700,000,000 shares.

• Proxies may vote on other business arising at the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends all proposals, including director elections and auditor ratification.